Category Archives: Biochemistry

Don Feria / Stanfordphoto.com

Jason Tarver spent 10 seasons with the 49ers before joining head coach David Shaw's staff at Stanford last year.

After reportedly striking out with five other candidates for their defensive-coordinator job, the Raiders turned to a man with a master's degree in biochemistry and molecular biology.

After finishing 29th in the NFL in total defense, they're hoping 37-year-old Jason Tarver can outsmart the rest of the AFC West.

They named the former 49ers aide as their coordinator Monday, replacing Chuck Bresnahan, whom former head coach Hue Jackson publicly upbraided after the team lost four of its last five games.

Tarver spent the last year as co-defensive coordinator for Stanford, which ranked either first or second in the Pac-12 in six defensive categories.

Before moving to the Farm, he had spent 10 years with the 49ers, starting as a quality-control coach for three years before moving to assistant running backs/offensive assistant coach. From 2005 to 2010, he coached the outside linebackers. He was hired by Steve Mariucci, then retained by a parade of successors. Jim Harbaugh would have kept him, too, except that David Shaw offered him a key spot on the Stanford staff.

Under Tarver's guidance in 2009, the 49ers' outside linebackers recorded 15 takeaways, 17.5 sacks and nine forced fumbles.

After playing safety at Foothill High in Pleasanton, he received a scholarship to play at Santa Clara, which soon dropped football. He transferred to play at West Valley College in Saratoga and later coached there while completing his degree in biochemistry at Santa Clara.

The son of a research scientist at Lawrence Livermore National Laboratory, Tarver got his master's at UCLA, but instead of going into drug research or medical school, he opted for coaching.

"I really love the look on guys' faces when you help them make a play," he told The Chronicle in September. "It's almost better than doing it yourself. That's what really made me want to do this."

This article appeared on page B - 3 of the San Francisco Chronicle

See the rest here:
Raiders hire Jason Tarver as def. coordinator

NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Strategic Analysis of the European Stem Cell Research Tools Market

http://www.reportlinker.com/p0769016/Strategic-Analysis-of-the-European-Stem-Cell-Research-Tools-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

The primary objective of this study is to measure brand perceptions of tools and technologies currently at the forefront of stem cell research: bio-imaging and microscopy, cell biology tools, immunochemicals, molecular biology tools, and protein biochemistry tools. The study also looks into the usage pattern of these tools. An extensive end-user survey was conducted with 25 laboratories to assess the requirement and usage of tools. Insightful review of key industry drivers, restraints and challenges have been discussed. Leading market players and the prevailing competitive landscape for each of the segments have been discussed.

Table of ContentsExecutive Summary 10-19

Executive Summary 11-13

Market Engineering Measurements 14

Scope & Objective 15

Technologies Employed for Stem Cell Research 16

Stem Cell Research Protocol 17

CEO's Perspective 18

Exchange Rates 19

Market Overview 19

Market Overview - Definitions 20-24

Market Overview 25-26

Market Overview - Segmentation 27

European Stem Cell Research End User Trends 28

Stem Cell Research Workflow 29

Purpose of Research and Profile of Respondents 30

Stem Cells and Tools Usage Trends 31-33

Tools and Equipment Budget for Stem cell research Tools 34

Market Outlook 35

Market Age 36

Funding for Stem Cell Program 37-39

External Challenges: Drivers and Restraints 40

Industry Challenges 41-45

Drivers & Restraints 46

Key Market Participants 52

Product Line Analysis 59

Forecasts and Trends -Total Stem Cell Research Tools Market 70

Forecast Assumptions 72

Revenue Forecasts 73-74

Bio Imaging Tools In Vivo and In Vitro Segment Breakdown 75

Revenue Forecasts 77-78

Market Share Analysis 79

Cell Biology, Protein Biochemistry, and Immunochemical Tools Segment Breakdown 80

Revenue Forecasts 82-83

Market Share Analysis 84

Molecular Biology Tools Segment Breakdown 85

Revenue Forecasts 87-88

Market Share Analysis 89

Demand Analysis 90

Bioimaging Tools In Vivo and In Vitro 92

Cell Biology Tools 93

Demand Analysis Molecular Biology Tools 94

Protein Biochemistry Tools 95

Immunochemical Tools 96

European Stem Cell Research Centers 97-99

SWOT Analysis 101-102

Strategic Recommendations and Conclusions 103-106

The Last Word 107

Appendix 110

List of Figures

Total Stem Cell Research Tools Market: Market Overview, Europe, 2010 25Total Stem Cell Research Tools Market: Tools Usage Trends, Europe, 2010 32-33Total Stem Cell Research Tools Market: Market Outlook, Europe, 2010 35Total Stem Cell Research Tools Market: R&D Programs Funded, Europe, 2006–2013 37Total Stem Cell Research Tools Market: Bioimaging Tools In Vivo and In Vitro End User Analysis, Europe, 2010 92Total Stem Cell Research Tools Market: Cell Biology Tools End User Analysis, Europe, 2010 93Total Stem Cell Research Tools Market: Molecular Biology Tools End User Analysis, Europe, 2010 94Total Stem Cell Research Tools Market: Protein Biochemistry Tools End User Analysis, Europe, 2010 95Total Stem Cell Research Tools Market: Immunochemical Tools End User Analysis, Europe, 2010 96

List of Charts

Percent Revenue Breakdown Total Stem Cell Research Tools Market: Europe, 2010 27

Percent Revenue Breakdown Total Stem Cell Research Tools Market: Europe, 2017 27

Total Stem Cell Research Tools Market: Purpose of Research and Profile of Respondents, Europe, 2010 30

Total Stem Cell Research Tools Market: General and Primary Focus on Stem Cell Research, Europe, 2010 31

Total Stem Cell Research Tools Market: Lab Budgets, Europe, 2010 34

Total Stem Cell Research Tools Market: Lab Budget Estimations, Europe, 2011 34

Total Stem Cell Research Tools Market: Segment Life Cycle Analysis, Europe, 2010 36

Total Stem Cell Research Tools Market: Industry Challenges, Europe, 2011–2017 41

Total Stem Cell Research Tools Market: Drivers and Restraints, Europe, 2010 46

Total Stem Cell Research Tools Market: Product Line Analysis, Europe, 2010 59-67

Market Overview Total Stem Cell Research Tools: Europe, 2010 71

Total Stem Cell Research Tools: Revenue Forecast, Europe, 2010–2017 73

Market Overview Bioimaging In Vivo and In Vitro Market: Europe, 2010 76

Bioimaging Tools In Vivo and In Vitro Market: Revenue Forecasts, Europe, 2010–2017 77

Bioimaging In Vivo and In Vitro Market: Market Share Analysis, Europe, 2010 79

Market Overview Cell Biology, Protein Biochemistry, and Immunochemical Tools Market: Europe, 2010 81

Cell biology, Protein Biochemistry, and Immunochemical Tools Market Revenue Forecasts, Europe, 2010–2017 82

Cell Biology, Protein Biochemistry, and Molecular Biology Tools Market: Market Share Analysis, Europe, 2010 84

Market Overview Molecular Biology Tools Market: Europe, 2010 86

Molecular Biology Tools Market: Revenue Forecasts, Europe, 2010–2017 87

Molecular Biology Tools Market: Market Share Analysis, Europe, 2010 89

Total Stem Cell Research Tools Market: Research Centers and Universities, Europe, 2010 98-100

Total Stem Cell Research Tools Market: SWOT Analysis, Europe, 2010 102

To order this report:Biological Therapy Industry: Strategic Analysis of the European Stem Cell Research Tools Market

More  

Market Research Report

Check our  

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

See more here:
Strategic Analysis of the European Stem Cell Research Tools Market

More Photos

Click thumbnails to enlarge

Telly (rear) is played by Angelo Williams.

Angelo Williams as Telly Monster, appearing in "Sesame Street Live: Elmo’s Super Heroes" at the Fisher Theatre.

By BETH ROBINSON
For Journal Register Newspapers

Former Detroiter Angelo Williams is touring with the company of "Elmo's Super Heroes" as Telly Monster.

Former Detroiter Angelo Williams has a degree in biochemistry; maybe as many stamps in his passport as Hillary Clinton; and a fuzzy purple alter ego.

Williams, 28, who graduated from Detroit’s High School of Arts, plays Telly Monster, one of the eponymous superheroes of “Sesame Street Live – Elmo’s Super Heroes.”

An “Army brat” born in Nuremberg, Germany, Williams was already well travelled before hitting Motown, Main Street and, finally, touring with Sesame Street. After graduating from high school, Williams did a year at Wayne State University before heading south to dance at Disney World in shows such as the Magic Kingdom’s Main Street Trolley Show and The Festival of the Lion King at Disney’s Animal Kingdom.

He credits a lot of water and Gatorade with his survival. “It’s a lot of hard work, especially in the summer when it’s 98 degrees when you’re in a button-up shirt and vest,” Williams said.

While in Orlando, Fla., he had a visit from a friend and fellow dancer from the Freedom Dance Expressions Company, who was touring with "Dragon Tales Live." Like "Sesame Street Live," it was produced by the VEE Corp. He spent time with the "Dragon Tales" company while they were performing in Orlando, and was invited to audition.

He began his first tour with "Sesame Street Live" in 2005, as Big Bird in “Super Grover Ready for Action,” the original version of the recently updated “Elmo’s Super Heroes.”

Williams has toured with each of the three touring casts of "Sesame Street Live" for the last seven years, playing both Big Bird and Telly, who was Williams’ favorite as a kid.

“He’s very quirky and he’s very spastic, too. He can be very upbeat and then be down a little,” said Williams.

The three casts tour the East Coast, the West Coast and the theater circuit with different shows, and each has international stops. Williams said his most interesting stop was Singapore. The company spent New Year’s Eve in Mexico City, where the soundtrack for the show is in Spanish.

He says that Sesame Street is every bit as beloved around the world as it is here at home. Continued...

“The show offers so much for all ages,” said Williams, whose favorite song in the current show is a take on “One” from “A Chorus Line.” “It’s like we’re in a Broadway show.”

Between tours, Williams earned a dual degree in dance education and biochemistry from the University of Central Florida. His residence is in Newark, Del.

He likes to read, and do gymnastics and has participated on competition cheer teams. The last book he read was the final Harry Potter book, which he saved for after seeing the movie, because he didn’t want to be disappointed. This way, Williams’ reasons, “The book just totally fills in the blanks.”

Asked if he’s interested in the movie business, Williams laughed. "Not unless I hit the lottery.”

Williams has a 6-year-old nephew and a niece on the way. His nephew has seen “every show I’ve been in since he was born. I’m the cool uncle.”

The next move for the multitalented Williams “is to figure out a longterm goal.” He says he is “getting ready for family mode” now, and would like to either open a dance studio and teach or put his biochemistry degree to work in research, where he’s leaning toward pharmaceuticals.

But his most immediate plan is to hustle off to Buffalo for another opening and another show of "Sesame Street Live."

Original post:
Multitalented Detroiter loves being Telly Monster in ' Sesame Street Live'

WINDSOR, ONTARIO--(Marketwire - Feb. 3, 2012) - Essex Angel Capital Inc. (TSX VENTURE:EXC.V - News) (the "Corporation" or "Essex") is pleased to announce that Denis Callewaert, Founder and Chief Science Officer of Wellness Indicators, Inc. ("Wellness Indicators"), one of the companies in the Essex portfolio, will be a guest speaker at the National Labor Management Conference in Hollywood, FL, February 16-21, 2012. Dr. Callewaert, who holds a Ph.D. in biochemistry, will be addressing the attendees about the unique aspects of Wellness Indicators' new wellness screening test, the Health Equater(TM) Assessment Profile.

One thousand attendees at the National Labor Management Conference will be offered the opportunity to participate in field trials of the Health Equater Assessment Profile, which is a quick and inexpensive urine test that screens for biomarkers indicating levels of wellness. The National Labor Management Conference is only one of the sites where the Health Equater Assessment Profile will be field-tested. Further field trials during the first quarter of 2012 will take place at a number of large insurance companies, large employers and organized labor unions. Wellness Indicators has field trial commitment letters from eight organizations, representing over 1,000,000 potential users, of whom 2,000 will be participating in field trials in the first quarter of 2012.

"Wellness Indicators is a game-changer in the Labor space," said Ed Hanley, former Chief Legal Counsel of Hotel Employees and Restaurant Employees and Bartenders International Union and current CEO of A&E Group Health Solutions LLC, "which brings a non-invasive, portable, affordable method for funds and their members to manage their own personal health. I am excited to share this new solution next week at the National Labor Conference, where some 1,000 different funds will be represented."

An international expert in biochemistry and immunology, with a focus on biomarkers for oxidative stress and inflammation, Dr. Callewaert has founded four biotechnology companies, including Wellness Indicators. The company plans to introduce the Health Equater Assessment Profile commercially, after field tests are completed.

The Health Equater Assessment Profile is a first-to-market test screening for such biomarkers as oxidative stress, low-grade inflammation and total antioxidant capacity, which indicate levels of wellness. Thousands of studies have shown that the biomarkers detected by the assessment profile are leading indicators for a variety of future health risks, including stroke, cancer, heart disease, and diabetes. The value of the Health Equater Assessment Profile is that it is non-invasive, results are ready in five minutes and it gives an indication at the individual level of how a person is functioning metabolically before the onset of chronic disease, when intervention is less expensive and more effective. Results are available in approximately five minutes, instead of the week that traditional lab tests require. Other advantages include ease of use, portability, and low cost, being approximately $30 per test, rather than around $100 for most current diagnostic tests.

"The field trials at the National Labor Management Conference, is a significant step forward for Wellness Indicators," said Rick Galdi, President and CEO of Essex. "The invitation for Dr. Callewaert to speak on the subject and the immediate availability to participate in the trial lays a strong foundation for future test sales."

This press release contains certain forward-looking statements about the future plans and intentions of companies in the Corporation's portfolio. Wherever possible, words such as "may," "will," "should," "could," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," or "potential," or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect Management's current beliefs and are based on information currently available to Management as at the date hereof. Forward-looking statements included or incorporated by reference in this press release include statements with respect to completion of Wellness Indicators' field trials in the first quarter of 2012, successful commercial launch of the Health Equator Assessment Profile later this year and the future business activity of Wellness Indicators.

Forward-looking statements involve significant risk, uncertainties, and assumptions. Many factors could cause actual results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Corporation cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Corporation assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

More:
Essex Angel Capital Inc. Announces: Wellness Indicators, Inc. Founder Is Guest Speaker at National Labor Management ...

MRSA can be split into two groups, based on where the person became infected. Typically, people in Britain become infected with MRSA in a hospital environment, when they are already sick and have a reduced ability to fight the bacteria.

Hospital acquired MRSA has been causing problems for decades and some success has been had in reducing infections in recent years. However, Dr. Ruth Massey is concerned about the emergence of a new MRSA bacterium over the past few years in the United States that is capable of infecting healthy people in the community.

Dr. Massey’s research, which has recently been published in the Journal of Infectious Disease, focused on why MRSA bacteria found in hospitals has not been able to migrate into the community, by comparing the hospital acquired bacteria with those causing community acquired infections.

Dr. Massey said: “Our research found that the composition of the cell wall of the bacteria is critical to the community acquired bacteria being more toxic.

“The ability of the MRSA bacteria to secrete toxins is one of the main ways it causes disease. Using a sensing system, it carefully controls when it switches on its ability to do this, so as not to cause disease until it is firmly established within the human.

“Many antibiotics target the cell walls of harmful bacteria, and to resist this, the bacteria have to make changes to their cell wall. We found that the sensing ability of the cell wall in hospital acquired MRSA bacteria is affected by these changes, causing them to reduce the amount of toxins they secrete when antibiotics are present. This means that the hospital strains cannot be both toxic and antibiotic resistant.”

However, the newer community acquired MRSA strains infect healthy people, where the composition of their cell walls is different, allowing them to sense their environment and switch toxin expression on at the right time.

Justine Rudkin, a PhD student working on the project, said: “The community acquired bacteria has evolved further, and is able to maintain a higher level of toxicity while also resisting treatment from antibiotics, making it a much larger problem. In the United States MRSA is the highest single cause of death from infectious disease, where it usually manifests itself as a skin infection that can result in abscesses, lethal cases of pneumonia and blood infections.

“While we are constantly learning more about MRSA, there is a serious threat posed by this newer strain of bacteria capable of causing disease and even death in perfectly healthy people. We need to respond seriously to this threat as it reaches Britain from the United States.”

Dr. Massey’s research into MRSA is funded by the Biotechnology & Biological Sciences Research Council (BBSRC) and the Medical Research Council (MRC). The research group is now looking for further funding to research potential treatments for community acquired MRSA.

Provided by University of Bath (news : web)

See more here:
Scientist warns of new MRSA threat

Newswise — KNOXVILLE— Barry D. Bruce, professor of biochemistry, cellular and molecular biology, at the University of Tennessee, Knoxville, is turning the term "power plant" on its head. The biochemist and a team of researchers have developed a system that taps into photosynthetic processes to produce efficient and inexpensive energy.

Bruce collaborated with researchers from the Massachusetts Institute of Technology and Ecole Polytechnique Federale in Switzerland to develop a process that improves the efficiency of generating electric power using molecular structures extracted from plants. The biosolar breakthrough has the potential to make "green" electricity dramatically cheaper and easier.

"This system is a preferred method of sustainable energy because it is clean and it is potentially very efficient," said Bruce, who was named one of "Ten Revolutionaries that May Change the World" by Forbes magazine in 2007 for his early work, which first demonstated biosolar electricity generation. "As opposed to conventional photovoltaic solar power systems, we are using renewable biological materials rather than toxic chemicals to generate energy. Likewise, our system will require less time, land, water and input of fossil fuels to produce energy than most biofuels."

Their findings are in the current issue of Nature: Scientific Reports.

To produce the energy, the scientists harnessed the power of a key component of photosynthesis known as photosystem-I (PSI) from blue-green algae. This complex was then bioengineered to specifically interact with a semi-conductor so that, when illuminated, the process of photosynthesis produced electricity. Because of the engineered properties, the system self-assembles and is much easier to re-create than his earlier work. In fact, the approach is simple enough that it can be replicated in most labs—allowing others around the world to work toward further optimization.

"Because the system is so cheap and simple, my hope is that this system will develop with additional improvements to lead to a green, sustainable energy source," said Bruce, noting that today's fossil fuels were once, millions of years ago, energy-rich plant matter whose growth also was supported by the sun via the process of photosynthesis.

This green solar cell is a marriage of non-biological and biological materials. It consists of small tubes made of zinc oxide—this is the non-biological material. These tiny tubes are bioengineered to attract PSI particles and quickly become coated with them—that's the biological part. Done correctly, the two materials intimately intermingle on the metal oxide interface, which when illuminated by sunlight, excites PSI to produce an electron which "jumps" into the zinc oxide semiconductor, producing an electric current.

The mechanism is orders of magnitude more efficient than Bruce's earlier work for producing bio-electricity thanks to the interfacing of PS-I with the large surface provided by the nanostructured conductive zinc oxide; however it still needs to improve manifold to become useful. Still, the researchers are optimistic and expect rapid progress.

Bruce's ability to extract the photosynthetic complexes from algae was key to the new biosolar process. His lab at UT isolated and bioengineered usable quantities of the PSI for the research.

Andreas Mershin, the lead author of the paper and a research scientist at MIT, conceptualized and created the nanoscale wires and platform. He credits his design to observing the way needles on pine trees are placed to maximize exposure to sunlight.

Mohammad Khaja Nazeeruddin in the lab of Michael Graetzel, a professor at the Ecole Polytechnique Federale in Lausanne, Switzerland, did the complex testing needed to determine that the new mechanism actually performed as expected. Graetzel is a pioneer in energy and electron transfer reactions and their application in solar energy conversion.

Michael Vaughn, once an undergraduate in Bruce's lab and now a National Science Foundation (NSF) predoctoral fellow at Arizona State University, also collaborated on the paper.

"This is a real scientific breakthrough that could become a significant part of our renewable energy strategy in the future," said Lee Riedinger, interim vice chancellor for research. "This success shows that the major energy challenges facing us require clever interdisciplinary solutions, which is what we are trying to achieve in our energy science and engineering PhD program at the Bredesen Center for Interdisciplinary Research and Graduate Education of which Dr. Bruce is one of the leading faculty."

The Bredesen Center is a joint UT/Oak Ridge National Laboratory academic unit. Bruce is also a co-principal investigator and scientific thrust leader in TN: SCORE, the Tennessee Solar Conversion and Storage Using Outreach, Research and Education. The $20 million project is funded by the NSF and focuses on promoting research and education on solar energy problems across Tennessee. Additionally, he co-founded and is associate director of UT's Sustainable Energy Education.

Bruce's work is funded by the Emerging Frontiers Program at the National Science Foundation.

Comment/Share

See original here:
Biosolar Breakthrough Promises Cheap, Easy Green Electricity